Cell­tri­on to build a $94M+ fa­cil­i­ty in South Ko­rea — re­port

Ko­re­an biosim­i­lar mak­er Cell­tri­on will be con­struct­ing a new man­u­fac­tur­ing fa­cil­i­ty in South Ko­rea.

A re­port from Ko­rea Bio­med­ical Re­view on Tues­day said that Cell­tri­on will spend KRW 126 bil­lion, or $94.4 mil­lion, on a new drug prod­uct man­u­fac­tur­ing fa­cil­i­ty lo­cat­ed at its cam­pus in Song­do, South Ko­rea, just south­west of Seoul.

The re­port said the new fac­to­ry is slat­ed to be fin­ished some­time in the be­gin­ning of 2026 and will start pro­duc­tion in 2027. The fa­cil­i­ty will al­so pro­duce “8 mil­lion liq­uid vials an­nu­al­ly.” The re­port did not give de­tails on the size or head­count at the fa­cil­i­ty. End­points News con­tact­ed Cell­tri­on for more in­for­ma­tion but did not get an im­me­di­ate re­sponse.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA